The OECD.AI Policy Navigator

Our policy navigator is a living repository from more than 80 jurisdictions and organisations. Use the filters to browse initiatives and find what you are looking for.

Accelerating Medicines Partnership


Added by:   National contact point
Added on:   09 Jul 2025
Updated by:   OECD analyst
Updated on:   25 Dec 2025

The Accelerating Medicines Partnership (AMP) program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical and life science companies, non-profit, and other organizations to transform the current model for developing new diagnostics and treatments.

Name in original language

Accelerating Medicines Partnership

Initiative overview

The initiative has the following objective(s):To transform the current model for developing new diagnostics and treatment.To jointly identify and validate promising biological targets for therapeutics.To increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

Name of responsible organisation (in English)

National Institutes of Health (NIH)|Food and Drug Administration (FDA)

About the policy initiative


Organisation:

  • National Institutes of Health (NIH)|Food and Drug Administration (FDA)

Category:

  • AI policy initiatives, programmes and projects

Initiative type:

  • AI use cases/projects in the public sector

Status:

  • Active

Start Year:

  • 2014

Binding:

  • Non-binding

Target Sectors:


Other relevant urls: